News from EUSA Pharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 27, 2017, 05:01 ET Dinutuximab beta erhält positive Empfehlung für die Behandlung von Hochrisiko-Neuroblastom in Europa

EUSA Pharma gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur ein positives Gutachten...


Mar 27, 2017, 04:00 ET EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe

EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, and Apeiron Biologics today...


Mar 27, 2017, 04:00 ET El dinutuximab beta recibe una recomendación positiva para el tratamiento del neuroblastoma de alto riesgo en Europa

EUSA Pharma ha anunciado hoy que el Comité de Medicamentos para Uso Humano (CHMP) de la Agencia Europea de Medicamentos ha emitido un dictamen...


Mar 27, 2017, 04:00 ET Dinutuximab beta reçoit une recommandation positive pour le traitement du neuroblastome à haut risque en Europe

EUSA Pharma a annoncé aujourd'hui que le Comité des médicaments à usage humain (CHMP) de l'Agence européenne des médicaments a émis un avis...


Oct 04, 2016, 04:00 ET EUSA Pharma Acquires Global Rights to Neuroblastoma Treatment Isqette® (Dinutuximab Beta) from Apeiron Biologics

EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced the acquisition of...


Sep 09, 2015, 04:00 ET EUSA Pharma Appoints William W Crouse to its Board of Directors

EUSA Pharma (EUSA), a recently-established specialty pharmaceutical company with global reach, today announced the appointment of William W Crouse...


Feb 02, 2012, 04:30 ET EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC® for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced...


Nov 18, 2011, 08:58 ET EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia

  EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today...


Jan 05, 2011, 05:16 ET EUSA Pharma Announces Priority Review Status for ERWINAZE(R) BLA

LANGHORNE, Pennsylvania and OXFORD, England, January 5, 2011 /PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused...


Nov 09, 2010, 05:00 ET EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that...


Nov 03, 2010, 07:46 ET EUSA Pharma Announces 10-Year Outcome Data Demonstrating Utility of PROSTASCINT(R) in Guiding Prostate Cancer Radiotherapy and Improving Disease-Free Survival

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the...


Sep 01, 2010, 04:59 ET EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment...


Jul 06, 2010, 03:59 ET EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has...